Dermatologic Surgery · 2007 · 29 citations · 7 references
MedicinePharmacologyClinical PharmacologyDrug DeliveryPharmacodynamicsEndothelial DysfunctionSystemic Sclerosis
BACKGROUND Sclerosants are used to treat vascular malformations. Owing to variations in the flow, the injected concentrations and the duration of exposure of these sclerosants are altered. Therefore, the clinical effectiveness of sclerotherapy is variable. OBJECTIVE The objective was to evaluate the differences in clinical response, usually observed among ethanol, polidocanol, and OK-432, using an in vitro sclerotherapy model. METHODS Endothelial cells were cultured and exposed to different concentrations of the sclerosants for 5 seconds and the remaining viable cells were counted using a MTT assay kit. Dyes were used to visualize the morphologic changes. Precipitant formation in blood was also evaluated. Finally, the degree of ICAM-1 expression, after exposure to lower concentrations of these sclerosants, was studied using immunocytochemistry. RESULTS Only ethanol causes precipitant formation and kills almost all cells from 30% concentration. Polidocanol begins to disrupt the cell membrane from 0.0125% onward. Only OK-432 induces ICAM-1 expression. CONCLUSION Ethanol's strong precipitant-forming effect may induce thromboembolism, thus enhancing sclerosis. Polidocanol's endothelial cell–lysing effect was clearly documented. OK-432 may mediate its effect by inducing inflammatory response of the endothelium via ICAM-1 expression. This in vitro model may be useful in evaluating other sclerosants as well.
7
Fabienne Mackay, H Loetscher, D Stueber et al. · The Journal of Experimental Medicine · 1993 · 392 citations · Full text
OK-432 therapy for lymphangioma in children: Why and how does it work?
Shuhei Ogita, T. Tsuto, Kaori Nakamura et al. · Journal of Pediatric Surgery · 1996 · 231 citations
Medicine, Oncology, Pediatrics +4